A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

Metabolic inflammation - a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)?

(2020) Nadine Gehrke et al.   GASTROENTEROLOGY

NAFLD 2020: The State of the Disease

(2020) Thomas G. Cotter et al.   GASTROENTEROLOGY

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease

(2020) James M. Paik et al.   HEPATOLOGY

Nonalcoholic Steatohepatitis

(2020) Adam C. Sheka et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease

(2020) Leonard Kaps et al.   United European Gastroenterology Journal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation

(2017) Marko Salmi et al.   ANTIOXIDANTS & REDOX SIGNALING

The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model

(2016) A G Jarnicki et al.   BRITISH JOURNAL OF PHARMACOLOGY

Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage?

(2016) Naga Chalasani et al.   GASTROENTEROLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Vascular adhesion protein 1 in nonalcoholic steatohepatitis: A novel biomarker?

(2015) Natalie J. Torok   HEPATOLOGY

MCPMod: AnRPackage for the Design and Analysis of Dose-Finding Studies

(2015) Björn Bornkamp et al.   Journal of Statistical Software

Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis

(2014) Chris J. Weston et al.   JOURNAL OF CLINICAL INVESTIGATION

Evolving therapies for liver fibrosis

(2013) Detlef Schuppan et al.   JOURNAL OF CLINICAL INVESTIGATION

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease

(2013) Kenneth Cusi et al.   JOURNAL OF HEPATOLOGY

Model-based dose finding under model uncertainty using general parametric models

(2013) José Pinheiro et al.   STATISTICS IN MEDICINE

VAP-1/SSAO Plasma Activity and Brain Expression in Human Hemorrhagic Stroke

(2011) Mar Hernandez-Guillamon et al.   CEREBROVASCULAR DISEASES

Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis

(2011) A. B. Jazwinski et al.   JOURNAL OF VIRAL HEPATITIS

Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes

(2009) Kousuke Noda et al.   EXPERIMENTAL EYE RESEARCH

Localization of vascular adhesion protein-1 (VAP-1) in the human eye

(2009) Lama Almulki et al.   EXPERIMENTAL EYE RESEARCH

Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease

(2008) W. Ray Kim et al.   HEPATOLOGY